ProQR Therapeutics NV
PRQR · NASDAQ
$1.38+$0.07 (+5.34%)TodayMarket closed ·
Prev close $1.31
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 12.4% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.1163 | -$0.08 | +31.2% |
| Q1 FY26 | -$0.122 | -$0.13 | −6.6% |
| Q4 FY25 | -$0.1035 | -$0.084 | +18.8% |
| Q3 FY25 | -$0.105 | -$0.10 | +4.8% |
| Q2 FY25 | -$0.0836 | -$0.12 | −43.5% |
| Q1 FY25 | -$0.0943 | -$0.10 | −6.0% |
| Q4 FY24 | -$0.0939 | -$0.0936 | +0.3% |
| Q3 FY24 | -$0.1076 | -$0.10 | +7.1% |
Earnings calls
- Shareholder/Analyst Call - ProQR Therapeutics N.V.
- Shareholder/Analyst Call - ProQR Therapeutics N.V.
- The Citizens Life Sciences Conference 2026
- Evercore 8th Annual Healthcare Conference
- Shareholder/Analyst Call - ProQR Therapeutics N.V.
- Shareholder/Analyst Call - ProQR Therapeutics N.V.
- Special Call - ProQR Therapeutics N.V.
- Special Call - ProQR Therapeutics N.V.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.